New concepts in understanding antiarrhythmic effects
- First Online:
- Cite this article as:
- Daccarett, M., Brachmann, J. & Schmidt, M. Clin Res Cardiol Suppl (2010) 5: 42. doi:10.1007/s11789-010-0010-2
- 8 Downloads
Radiofrequency catheter ablation (RFCA) has been established as a curative alternative to antiarrhythmic drug (AAD) therapy in patients with supraventricular arrhythmias other than atrial fibrillation (AF). Many currently used AAD have limited efficacy and cause cardiac and extracardiac adverse effects. There is a need for new AADs with high efficacy and a favorable safety profile in AF patients. Dronedarone and vernakalant are promising new agents with a low risk profile up to date. Effectively restoring sinus rhythm is a crucial aspect in heart failure (HF) patients with AF. RFCA, including pulmonary vein isolation and other left and right atrial ablation targets, offers the possibility of long-term suppressive or curative therapy of AF. New antiarrhythmic drug and interventional concepts in AF and HF patients are discussed.